Does Medical Cannabis Help With Cancer Symptoms? A Rigorous Trial Says Mostly No

Double-blind, placebo-controlled randomized clinical trial. 144 patients with advanced cancer randomized to medicinal cannabis (1:1 THC:CBD at 10 mg/ml) or placebo oil. Dose escalated over 14 days based on tolerance and efficacy, continued to day 28. Primary outcome: change in Total Symptom Distress Score (TSDS) at day 14 using the Edmonton Symptom Assessment Scale. Multiple secondary outcomes including individual symptoms, opioid use, quality of life, and global impression of change.

Many cancer patients use or want to use cannabis for symptom relief, often based on anecdotal reports. This trial provides high-quality evidence that while cannabis may help specifically with pain, it doesn't improve the overall symptom burden beyond what good palliative care provides. That's important information for patients making treatment decisions and for oncologists being asked about cannabis.

This connects to RTHC-00161's finding that medical marijuana laws were associated with reduced opioid prescriptions after cancer surgery. Together, they suggest cannabis may play a specific role in cancer pain management—but not as a general symptom cure-all. The pain-specific benefit aligns with the broader pain literature on cannabinoids, while the null result for other symptoms echoes the mixed evidence for cannabis in nausea, appetite, and mood.

28-day trial duration may be too short for some benefits to emerge. The 1:1 THC:CBD ratio and oil formulation may not represent all cannabis products—different ratios, inhaled routes, or higher doses might produce different results. Both groups improved substantially, making it harder to detect additional cannabis benefit. Pain finding was a secondary outcome.